AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05749614
Drug: Lidocaine cream
RxNorm normalized name: Neomycin and Polymyxin B Sulfates and Lidocaine Cream
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 1 was given 1 ml of 5% lidocaine cream on demand. They were instructed to apply the lidocaine cream evenly in a circular pattern to the glans penis without precise application to the sensitive area of the glans penis. The treatment lasted for a total of 4 weeks.
Trial: NCT05749614
Drug: Lidocaine cream
RxNorm normalized name: Neomycin and Polymyxin B Sulfates and Lidocaine Cream
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 2 had a penile biological vibration threshold test performed to detect loci with a lower threshold. They were instructed to apply 1 ml of 5% lidocaine cream to the sensitive loci on the glans penis for 4 weeks.
Trial: NCT04956289
Drug: Viltolarsen
RxNorm normalized name: Viltolarsen
DrugBank: Viltolarsen (DB15005)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Received during weekly intravenous infusions
Trial: NCT05501158
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suggesting an increase in the dose of tamoxifen to those who have suboptimum level of endoxifen due to their genetic variations
Trial: NCT05951504
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with an odontogenic cervicofacial infection were randomized between two intervention groups. Patients in one group were treated with one dose of Solumedrol 125mg intravenous at time of surgery. Patients with an odontogenic cervicofacial infection in the other group were treated with one dose of Solumedrol 125mg intravenous at time of surgery, as well as three consecutive doses of Solumedrol 125mg intravenous every six hours post-operatively. Remainder of management was as per protocol.
Trial: NCT06454383
Drug: Cholestyramine
RxNorm normalized name: Cholestyramine
DrugBank: Cholestyramine (DB01432)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06454383
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06454383
Drug: Leflunomide
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04718051
Drug: Shen Pu Yang Gan Wan
RxNorm normalized name: Ren shen
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shen Pu Yang Gan Wan is Traditional Chinese Medicine; in addition, it has a high dose.
Trial: NCT05351762
Drug: Nimotuzumab Combined With Neoadjuvant Chemotherapy
RxNorm normalized name: miconazole
DrugBank: Nimotuzumab (DB06192)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The study arm received nimotuzumab (400mg, every three weeks, for 2 weeks) combined with TPF chemotherapy
Trial: NCT06508125
Drug: cross-linked hyaluronic acid
RxNorm normalized name: riboflavin 5'-phosphate
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cross-linked hyaluronic acid injection with physical therapy
Trial: NCT06508125
Drug: non-cross-linked hyaluronic acid
RxNorm normalized name: riboflavin 5'-phosphate
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: non-cross-linked hyaluronic acid injection with physical therapy
Trial: NCT05183828
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04489719
Drug: Radium Ra 223 Dichloride
RxNorm normalized name: Radium Ra 223 dichloride
DrugBank: Radium Ra 223 dichloride (DB08913)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05035953
Drug: Edaravone Dexborneol
DrugBank: Borneol (DB11288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone Dexborneol 37.5 mg (containing Edaravone 30 mg and Dexborneol 7.5 mg), BID, 14 days, addition to thrombolysis
Trial: NCT05833672
Drug: Terelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: q3w Terelizumab 200mg on day 1 of each cycle
Trial: NCT05909436
Drug: GLS-012
RxNorm normalized name: GL-2045
DrugBank: GL-2045 (DB16971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the dose escalation stage of GLS-012 monotherapy, RP2D will be determined. All subjects will receive GLS-012 intravenously Q3W.~In the expansion stage of GLS-012 monotherapy, subjects will receive up to 17 doses of GLS-012 at the RP2D administered Q3W.~In the dose escalation stage of GLS-012 combination with GLS-010, RP2D of GLS-012 in combination with a fixed-dose GLS-010 will be determined. All subjects will receive GLS-012 and GLS-010 intravenously Q3W.~In the expansion stage of GLS-012 combination with GLS-010, subjects will receive up to 35 doses of GLS-012 at the RP2D and GLS-010 at a fixed dose administered Q3W.
Trial: NCT05909436
Drug: GLS-010
RxNorm normalized name: Anti-pd-1 monoclonal antibody gls-010
DrugBank: Zimberelimab (DB17505)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the dose escalation stage of GLS-012 combination with GLS-010, RP2D of GLS-012 in combination with a fixed-dose GLS-010 will be determined. All subjects will receive GLS-012 and GLS-010 intravenously Q3W.~In the expansion stage of GLS-012 combination with GLS-010, subjects will receive up to 35 doses of GLS-012 at the RP2D and GLS-010 at a fixed dose administered Q3W.
Trial: NCT06228456
Drug: Ticagrelor 60mg
RxNorm normalized name: TICAGRELOR 60MG TAB
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the ticagrelor arm will receive a 180 mg loading dose of ticagrelor followed by ticagrelor 60 mg bid maintenance dose for 30±5 days. Patients will maintain aspirin 81 mg once daily for the duration of the study.
Trial: NCT06228456
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients in the clopidogrel arm will continue to receive clopidogrel 75 mg/daily for 30±5 days. Patients will maintain aspirin 81 mg once daily for the duration of the study.
Trial: NCT04716569
Drug: intranasal ivermectin spray
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: usage of ivermectin as intranasal spray for treating early covid patiens
Trial: NCT06348576
Drug: AD-209
RxNorm normalized name: Stahist AD
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PO, Once daily(QD), 8weeks
Trial: NCT06348576
Drug: AD-2091
RxNorm normalized name: Stahist AD
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PO, Once daily(QD), 8weeks
Trial: NCT06345404
Drug: Soquelitinib
RxNorm normalized name: Soquelitinib
DrugBank: Soquelitinib (DB18749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT00061776
Drug: Capsaicin Dermal Patch
RxNorm normalized name: capsaicin Medicated Patch
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06316180
Drug: drospirenone/estetrol 3mg/14.2mg
DrugBank: Drospirenone (DB01395)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hysteroscopic polipectomy after starting 14-day treatment with oral drospirenone/estetrol 3mg/14.2mg at any time of the menstrual cycle.
Trial: NCT00292760
Drug: Alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05626348
Drug: Iguratimod
RxNorm normalized name: Iguratimod
DrugBank: Iguratimod (DB12233)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
Trial: NCT05626348
Drug: Adalimumab Injection
RxNorm normalized name: adalimumab Injection
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab Injection，40mg，iH，every two weeks (q2w) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
Trial: NCT05626348
Drug: Leflunomide
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leflunomide，20mg, po, quaque day (qd) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
Trial: NCT05626348
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine，200mg, po, twice per day (bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
Trial: NCT05545436
Drug: Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine ) Drug: Camrelizumab 200mg Drug: oxaliplatin 130 mg/m2 Drug: Teggio 40 mg/m2 Drug: oxaliplatin 130 mg/m2 Drug: capecitabine 1000 mg/m2 Q3W for 3 cycles. Radical surgery was performed 3 weeks after the last neoadjuvant treatment.
Trial: NCT05894928
Drug: LOXO-783
RxNorm normalized name: Loxoprofene
DrugBank: Loxoprofen (DB09212)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Administered orally.
Trial: NCT05894928
Drug: Cholestyramine
RxNorm normalized name: Cholestyramine
DrugBank: Cholestyramine (DB01432)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04727164
Drug: HBM4003 and Triprilimab
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will be treated with HBM4003 on Day 1 Cycle 1 and be treated with HBM4003 and Triprilimab during each 21-day cycles from Cycle 2 in part 1.Subjects will be treated with HBM4003 and Triprilimab on Day 1 during each 21-day cycle in part 2.
Trial: NCT04181736
Drug: Guanfacine Tablets
RxNorm normalized name: Guanfacine Tablets
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Guanfacine immediate release, sold under the brand name Tenex among others, is a medication used to treat high blood pressure and off-label to treat attention deficit hyperactivity disorder (ADHD). It is taken by mouth and will be compounded by a pharmacy to the required doses used in this study.
Trial: NCT04813406
Drug: Anlotinib + Sintilimab
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib: 1 capsule (10mg) once a day, d1-d14 per cycle, 3 weeks for a treatment cycle.~Sintilimab: 200 mg/time, intravenous injection, every 3 weeks is one cycle.
Trial: NCT05616455
Drug: Propionibacterium Acnes
RxNorm normalized name: PROPIONIBACTERIUM ACNES
DrugBank: Propionibacterium acnes (DB19089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of the gel every 12 hours for 40 days
Trial: NCT05616455
Drug: glyceryl trinitrate
RxNorm normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Application of the gel every 12 hours for 40 days
Trial: NCT06678451
Drug: Sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: When T2 appeared, the sugammadex group was given 2mg/kg of sugammadex intravenously (adjusted body weight), the neostigmine group was given 0.04mg/kg of neostigmine + 0.02mg/kg of atropine intravenously (adjusted body weight).
Trial: NCT06678451
Drug: Neostigmine
RxNorm normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: When T2 appeared, the neostigmine group was given 0.04mg/kg of neostigmine + 0.02mg/kg of atropine intravenously (adjusted body weight).
Trial: NCT04014712
Drug: Tetrahydrobiopterin
RxNorm normalized name: tetrahydrobiopterin
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral, Single dose
Trial: NCT05637398
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The active treatment intervention consists of colchicine 0.5 mg twice daily that will be administrated by the investigator
Trial: NCT06099938
Drug: sufentanil, ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study used conventional anesthetic drugs to compare the effects of the two drugs on maternal and infant blood flow
Trial: NCT06336993
Drug: herbal compound
RxNorm normalized name: BENZOIN COMPOUND
DrugBank: Benzoin (DB14020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients were instructed to take the herbal compound twice a day for 3 weeks, 200 to 300ml each time, composition of herbal compound of BSTL was BaiShao 9g, ChuanNiuXi 15g, DanShen 15g, DiLong 9g, DuHuo 9g, DuZhong 15g, GouJi 15g, QinJiao 9g, SangJiSheng 15g, XiXianCao 9g, XuChangQin 9g and YanHuSuo 9g, and herbs were provided by the Traditional Chinese Medicine pharmacy of Tongde Hospital in Zhejiang Province.
Trial: NCT05702905
Drug: Metformin Hydrochloride 500 MG
RxNorm normalized name: metformin hydrochloride 500 MG
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin oral tablet (500mg per tablet) will be administered in a dose increasing mode: the initial dose will be 500mg twice daily, which will be increased to 1000mg twice daily after two weeks, and then maintained until the end of treatment in total 12 weeks.
Trial: NCT05702905
Drug: Semaglutide, 1.34 mg/mL
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inject semaglutide subcutaneously once weekly, on the same day each week, at any time of day, in a dose increasing mode: the initial dose of 0.25mg QW (once a week), increased to 0.5mg QW after 4 weeks, and increased to 1.0mg QW after another 4 weeks, and then maintained 1.0mg until the end of treatment in total 12 weeks.
Trial: NCT05702905
Drug: Semaglutide, 1.34 mg/mL and Metformin Hydrochloride 500 MG
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Both Semaglutide injection and Metformin oral tablet will be administered as described above.
Trial: NCT06411795
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given via epidural and injection
Trial: NCT06411795
Drug: Hydromorphone
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given via epidural
Trial: NCT06411795
Drug: Iopamidol
RxNorm normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given via epidural
Trial: NCT06411795
Drug: Liposomal Bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given injection
Trial: NCT06411795
Drug: Thoracic Epidural Analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo thoracic epidural placement
Trial: NCT06213727
Drug: lowe-dose ZKY001 eye drops
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: eye drops
Trial: NCT06213727
Drug: Medium-dose ZKY001 eye drops
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eye drops
Trial: NCT06213727
Drug: ZKY001 simulated eye drops
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: eye drops
Trial: NCT00872950
Drug: 3,4-DIAMINOPYRIDINE
RxNorm normalized name: 3,4-Diaminopyridine
DrugBank: Amifampridine (DB11640)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment will begin with a low dose and will be increased as clinically needed as tolerated. The upper limit will be a total of 100mg/day.
Trial: NCT00002310
Drug: Crofelemer
RxNorm normalized name: Crofelemer
DrugBank: Crofelemer (DB04941)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02588807
Drug: Spirit1
RxNorm normalized name: TURPENTINE SPIRITS
DrugBank: Turpentine (DB11120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirit 1 is a combination of phospholipids and anti-oxidant medicinal plants
Trial: NCT05878899
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic dose of enoxaparin once daily for 10 days after delivery.
Trial: NCT05341154
Drug: Ketamine Hcl 50Mg/Ml Inj
RxNorm normalized name: KETAMINE HCL 50MG/ML INJ
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be given the active comparator or placebo only once right before the induction of anesthesia.
Trial: NCT04922827
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: single intravenous administration of 5 milligrams/kilogram
Trial: NCT06375915
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Following radioembolization, for 6 cycles -intravenous infusion on day 1 of each cycle
Trial: NCT06375915
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Following radioembolization, for 6 cycles -intravenous infusion on day 1 and 8 of each cycle
Trial: NCT06375915
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Following radioembolization, for 6 cycles -intravenous infusion on day 1 and 8 of each cycle
Trial: NCT05319574
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg q3w for two cycles administrated concurrently with chemotherapy
Trial: NCT04769440
Drug: mg sulphate
RxNorm normalized name: MG 217 Psoriasis
DrugBank: Glyceryl 1-oleate (DB13171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mgso4 infusion will start 15 minutes after intubation , 30 mg/kg LBW of 10%mgso4 in 100 ml normal saline I.V ,over 30 minutes followed by 10 mg/kg LBW for 90 minutes
Trial: NCT00505258
Drug: ceftobiprole medocaril
RxNorm normalized name: Ceftobiprole medocaril
DrugBank: Ceftobiprole medocaril (DB14733)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04922554
Drug: Omadacycline Oral Tablet
RxNorm normalized name: omadacycline Oral Tablet
DrugBank: Omadacycline (DB12455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: omadacycline 300 mg orally, once daily (150 mg tablets x 2)
Trial: NCT05141474
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive sequential doses of 720,000 IU/kg IV IL-2 every 8-24 hours depending on patient tolerance. It will be administered on Days 0 to 2, starting between 3 and 24 hours after the completion of NEXTGEN-TIL infusion.~IL-2 doses may be skipped in case of toxicity. If 2 sequential doses or more than 2 non-sequential doses of IL-2 are skipped due to patient intolerance or the discretion of the investigator, IL-2 administration must be stopped.
Trial: NCT06660394
Drug: LP352
RxNorm normalized name: Linzagolix
DrugBank: Linzagolix (DB17083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube
Trial: NCT04408924
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally
Trial: NCT06038084
Drug: Erdos capsule
RxNorm normalized name: erdosteine
DrugBank: Erdosteine (DB05057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three times a day
Trial: NCT05490095
Drug: SVG101 (T)
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg of SVG101
Trial: NCT05490095
Drug: Afinitor (R)
RxNorm normalized name: Afinitor
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5mg of Afinitor
Trial: NCT05754528
Drug: Standard of care administration of Endocrine therapy
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard daily dosing of endocrine therapy. Defined as taking endocrine therapy every day from the start.
Trial: NCT05754528
Drug: Dose-frequency escalation administration of Endocrine therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endocrine therapy dose-frequency escalation. Defined as taking endocrine therapy every other day for 1 month and then daily.
Trial: NCT06359275
Drug: PD-1
RxNorm normalized name: NPD-1
DrugBank: PD-168393 (DB07662)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab，240 mg/time，D1， Q3W
Trial: NCT06359275
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel, 125mg/m2，IV，D1，8, Q3W
Trial: NCT06359275
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine，1000mg/m2，IV，D1，8，Q3W
Trial: NCT05995769
Drug: Psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dosing session followed by 5 MET weekly sessions starting 24hrs after dosing
Trial: NCT00003514
Drug: antineoplaston A10
RxNorm normalized name: Antineoplaston A10
DrugBank: Antineoplaston A10 (DB11702)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003514
Drug: antineoplaston AS2-1
RxNorm normalized name: ANTINEOPLASTON AS2-1 COMPONENT PHENYLACETIC ACID
DrugBank: Phenylacetic acid (DB09269)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00053339
Drug: tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00053339
Drug: trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes